<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394482</url>
  </required_header>
  <id_info>
    <org_study_id>17481A</org_study_id>
    <secondary_id>2017-001335-39</secondary_id>
    <nct_id>NCT03394482</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Lu AF35700</brief_title>
  <official_title>Interventional, Randomized, Open-label, Three-group, Two-sequence Crossover, Single-dose, Bioequivalence Study of Lu AF35700 in Healthy Subjects Comparing the 5, 10 and 20 mg Commercial Tablet (Test) to the 5, 10 and 20 mg Clinical Tablet (Reference)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish bioequivalence of Lu AF35700 between the clinical
      formulation and the commercial formulation for three tablet strengths; 5, 10 and 20 mg
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">July 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-72h of Lu AF35700</measure>
    <time_frame>zero to 72 hours</time_frame>
    <description>Area under the Lu AF35700 plasma concentration-time curve from zero to 72 hours post-dose (AUC0-72h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Lu AF35700</measure>
    <time_frame>zero to 72 hours</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of Lu AF35700</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of Lu AF35700</measure>
    <time_frame>zero to 72 hours</time_frame>
    <description>Time to occurance of Cmax of Lu AF35700</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of Lu AF35700</measure>
    <time_frame>zero to time of the last quantifiable plasma concentration</time_frame>
    <description>Area under the Lu AF35700 concentration-time curve from zero to time of the last quantifiable plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AF35700 5 mg clinical formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AF35700 5 mg commercial formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AF35700 10 mg clinical formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AF35700 10 mg commercial formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AF35700 20 mg clinical formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AF35700 20 mg commercial formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 5 mg clinical formulation</intervention_name>
    <description>Lu AF35700 tablets 5 mg oral single dose</description>
    <arm_group_label>Lu AF35700 5 mg clinical formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 5 mg commercial formulation</intervention_name>
    <description>Lu AF35700 tablets 5 mg oral single dose</description>
    <arm_group_label>Lu AF35700 5 mg commercial formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 10 mg clinical formulation</intervention_name>
    <description>Lu AF35700 tablets 10 mg oral single dose</description>
    <arm_group_label>Lu AF35700 10 mg clinical formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 10 mg commercial formulation</intervention_name>
    <description>Lu AF35700 tablets 10 mg oral single dose</description>
    <arm_group_label>Lu AF35700 10 mg commercial formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 20 mg clinical formulation</intervention_name>
    <description>Lu AF35700 tablets 20 mg oral single dose</description>
    <arm_group_label>Lu AF35700 20 mg clinical formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 20 mg commercial formulation</intervention_name>
    <description>Lu AF35700 tablets 20 mg oral single dose</description>
    <arm_group_label>Lu AF35700 20 mg commercial formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women aged ≥18 and ≤55 years

          -  Body Mass Index (BMI) of ≥18.5 and ≤32 kg/m2

          -  Subject must be in good general health as assessed using medical history, clinical
             laboratory tests, and physical examination

        Exclusion Criteria:

          -  The subject must not be of childbearing potential (if a woman) or should use
             contraception, be surgically sterilized or not be sexually active (both sexes). Women
             must not be pregnant or lactating

          -  The subject must not be a CYP2D6 or a CYP2C19 poor metaboliser

          -  The subject has previously been dosed with Lu AF35700

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H.Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H.Lundbeck A/S</last_name>
    <phone>+4536301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

